Inhibikase seeks FDA feedback about proposed trial for IkT-001Pro
Inhibikase Therapeutics is meeting with the U.S. Food and Drug Administration (FDA) April 5 to discuss the potential of its experimental formulation of imatinib, dubbed IkT-001Pro, for pulmonary arterial hypertension (PAH). “Following our … discussion with the FDA related to the path to approval for IkT-001Pro in up…